Edmond DE Rothschild Holding S.A. Has $13.51 Million Stock Holdings in Bristol Myers Squibb Company $BMY

Key Points

• Edmond DE Rothschild Holding S.A. reduced its stake in Bristol Myers Squibb Company by 17%, selling 45,342 shares, leaving them with 221,517 shares valued at $13.51 million.
• Insider trading activity included EVP David V. Elkins selling 56,000 shares at an average price of $47.33, resulting in a total of approximately $2.65 million.
• Bristol Myers Squibb's quarterly earnings report showed an EPS of $1.46, exceeding expectations, along with a dividend payment of $0.62 per share, marking a yield of 5.2%.

Edmond DE Rothschild Holding S.A. lessened its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 17.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 221,517 shares of the biopharmaceutical company's stock after selling 45,342 shares during the period. Edmond DE Rothschild Holding S.A.'s holdings in Bristol Myers Squibb were worth $13,510,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of BMY. Pinney & Scofield Inc. bought a new position in shares of Bristol Myers Squibb during the 4th quarter valued at about $25,000. Park Square Financial Group LLC acquired a new stake in Bristol Myers Squibb in the 4th quarter valued at approximately $26,000. Global Wealth Strategies & Associates raised its position in Bristol Myers Squibb by 137.5% in the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 275 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Bristol Myers Squibb in the 1st quarter valued at approximately $31,000. Finally, Accent Capital Management LLC acquired a new stake in Bristol Myers Squibb in the 1st quarter valued at approximately $33,000. Institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Stock Performance

Shares of BMY stock traded down $0.46 during trading on Monday, reaching $46.68. 9,995,942 shares of the company's stock were exchanged, compared to its average volume of 13,053,416. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The stock has a market capitalization of $95.02 billion, a PE ratio of 18.82, a PEG ratio of 2.41 and a beta of 0.35. Bristol Myers Squibb Company has a twelve month low of $42.96 and a twelve month high of $63.33. The firm's fifty day moving average price is $47.09 and its 200-day moving average price is $50.44.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The business had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. During the same period in the previous year, the firm earned $2.07 EPS. The firm's revenue was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.3%. The ex-dividend date of this dividend was Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is 100.00%.

Insider Activity

In other news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the sale, the executive vice president directly owned 167,379 shares of the company's stock, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.07% of the company's stock.

Analysts Set New Price Targets

BMY has been the topic of a number of recent research reports. Morgan Stanley reissued a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Daiwa Capital Markets lowered Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 target price on the stock. in a research report on Tuesday, August 5th. Citigroup dropped their target price on Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research report on Friday, August 1st. Daiwa America lowered Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Finally, Wall Street Zen lowered Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $56.38.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.